Upstream Bio, Inc. (UPB) investor relations documents from the company's IR site: 4 press releases. Read in-app with summaries. First-party data.
| Published | Type | Document |
|---|---|---|
| 2026-08-11 | Press release | Upstream Bio Reports Second Quarter 2026 Financial Results |
| Press release | Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights | |
| Press release | Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financi | |
| 2024-09-09 | Press release | Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress |
UPB overview · UPB earnings · UPB financials · UPB KPIs · UPB ownership · UPB peers · UPB filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.